Humacyte, Inc. HUMA

0.56 (0.01) (1.75%) as of 25 Sep
Market cap
$166.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 0.00 0.00 — — 0.00
P/S ratio
— — 0.00 229.44 138.94 — — 74.50
P/FCF ratio
— — 0.00 0.00 0.00 — — 0.00
P/Operating CF
— — (462.70) (13.51) (11.47) — — (5.81)
P/B ratio
— — 1.13 2.37 1.86 — — 48.84
Price to Tangible BV
— — 1.13 2.37 1.86 — — 48.84
EV/Sales
— — 0.00 90.88 73.88 — — 81.59
EV/EBITDA
— — 0.00 0.00 0.00 — — 0.00
EV/Operating CF
— — 0.00 (1.41) (1.63) — — (1.58)
EV/FCF
— — 0.00 (1.41) (1.60) — — (1.57)
Quick Ratio
— — 3.56 20.42 7.76 4.36 2.25 2.77
Current Ratio
— — 3.69 20.75 7.88 4.52 2.40 3.69
Net Debt/EBITDA
— — 0.30 2.46 1.51 0.70 0.29 (0.12)
Debt/Assets
0.00% 0.00% 21.64% 16.92% 19.18% 12.71% 9.88% 53.64%
Debt/Equity
— — (0.07) 0.40 0.34 1.20 (0.26) 20.08
Asset Turnover
— 0.00 0.03 0.01 0.01 0.00 0.00 0.02
Operating CF/Net income
— — 0.84 3.07 5.94 0.66 0.66 2.57
Capex/Depreciation
— — (0.03) (0.02) (0.11) (0.28) (0.22) (0.12)
Interest Coverage
— — 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— — 58.32% 23.21% (10.01%) (169.81%) 760.17% 164.78%
ROA
— 0.00% (124.71%) (13.47%) (4.88%) (66.63%) (111.77%) (32.12%)
ROIC
— — 0.00% 0.00% (1,247.32%) 0.00% 0.00% (449.67%)
Return on Tangible Assets
— — (93.44%) (10.45%) (7.27%) (120.90%) (291.75%) (60.08%)
Average Days of Receivables
— — 27.66 50.86 7.23 — — 78.98
Research and Development Expense of Revenue
— — 3,626.96% 4,856.77% 4,042.17% 0.00% 0.00% 3,400.49%
Selling, General and Administrative Expense of Revenue
— — 805.70% 1,673.00% 1,462.17% 0.00% 0.00% 1,529.49%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— — 314.82% 803.33% 395.14% 0.00% 0.00% 478.56%
Graham Net Nets
— — (0.07) 0.22 0.31 — — (0.30)
Graham Number
— — 0.00 0.00 0.00 — — 0.00
Earnings Yield
— — (0.20%) (91.86%) (5.69%) — — (20.83%)
Free Cash Flow Yield
— — 0.00% (28.09%) (33.19%) — — (69.76%)
Revenue per Share
— — 0.26 0.03 0.02 0.00 0.00 0.01
Operating CF per Share
— — (9.64) (2.03) (0.69) (0.71) (0.83) (0.66)
Capex per Share
— — (0.05) (0.01) (0.01) (0.02) (0.01) (0.01)
Free Cash Flow per Share
— — (9.68) (2.04) (0.70) (0.73) (0.84) (0.67)
Cash per Share
— — 6.93 5.64 1.47 0.78 0.38 0.32
Shareholders Equity per Share
— — (60.76) 3.06 1.13 0.13 (0.44) 0.02
Interest Debt per Share
— — 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— — (60.76) 3.06 1.13 0.13 (0.44) 0.02
Free Cash Flow
— — (55.84) (81.41) (72.18) (75.58) (99.69) (105.93)
Working Capital
— — 30.22 218.29 134.63 64.84 27.91 49.42
Capital Expenditures
— — (0.27) (0.22) (1.05) (2.28) (1.57) (0.88)
Net Current Asset Value
— — (415.56) 64.98 66.83 (31.40) (142.68) (45.46)
EV/EBIT
— — 0.00 0.00 0.00 — — 0.00
Capex to Sales
— — 0.18 0.17 0.67 0.00 0.00 0.43
Net Profit Margin
— — (4,461.70%) (2,096.36%) (764.54%) 0.00% 0.00% (2,003.58%)
Price to Operating Income
— — 0.00 0.00 0.00 — — 0.00
Other line items
Depreciation/Fixed assets
— — 0.20 0.26 0.32 0.31 0.31 0.40
Cash ROIC
— — 33.60% (29.34%) (32.85%) (90.76%) (2,058.17%) (106.52%)
Accounts Receivable Turnover
— — 10.32 8.74 15.12 — — 8.64
Accounts Payable Turnover
— — 3.86 3.79 4.48 0.00 0.00 1.96
Inventory Turnover
— — 0.00 0.00 0.00 — — 0.00
Average Days of Payables
— — 98.44 92.27 70.52 0.00 0.00 203.30
Days of Inventory on Hand
— — 0.00 0.00 0.00 — — 511.23
Average Receivables
— — 0.14 0.14 0.10 — — 0.24
Average Payables
— — 2.18 2.18 1.84 4.04 5.49 4.95
Average Assets
— 0.00 53.34 196.61 245.42 166.26 133.05 127.12
Average Common Equity
— — (114.07) (114.07) 119.55 65.24 (19.56) (24.78)

Fold the line items

Columns are period end dates